A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: Apixaban

  • Apixaban (Eliquis) – Hospital Guideline

    Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of  stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on  Dec 28th, 2012 is here).  Here is the management guideline for apixaban

  • Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…

  • Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants

    There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1].  This…

  • Apixaban (Eliquis): Good News

    Eliquis (Apixaban) is one of the 4 promising new oral anticoagulants that (a) do not require routine monitoring of its anticoagulant effect and (b) work independently of the vitamin K pathway.

  • Eliquis (Apixaban) – Good News

    Eliquis (Apixaban) is one of the 4 promising new oral “blood thinners” that (a) do not require monitoring of its “blood thinning” (anticoagulant) effect, i.e. do not require INR monitoring, and (b) do not interfere with vitamin K in the diet, i.e. patients can eat what they want.

  • Apixaban (Eliquis): Another New Oral “Blood Thinner”

    Good news. Another one of the new oral “blood thinners” in development,  Apixaban (Eliquis®), has moved forward. On May 23rd, 2011 the European Medicines Agency (EMA) approved Eliquis® for marketing in the 27 countries of the European Community for DVT prevention after orthopedic surgery (hip and knee replacement). In the U.S., Eliquis® is not yet FDA approved, and still…

  • Pradaxa Approval – Great News!

    The new oral anticoagulant Pradaxa® (Dabigatran) was approved by the FDA on October 20th, 2010 [ref 1,2]. As of Feb 3rd, 2012, Pradaxa® is only FDA approved for use in patients with atrial fibrillation. It is not approved yet for patients with DVT and PE.